DK2283156T3 - Detection of genetic predisposition to conditions associated with osteoarthritis - Google Patents
Detection of genetic predisposition to conditions associated with osteoarthritis Download PDFInfo
- Publication number
- DK2283156T3 DK2283156T3 DK09740020.4T DK09740020T DK2283156T3 DK 2283156 T3 DK2283156 T3 DK 2283156T3 DK 09740020 T DK09740020 T DK 09740020T DK 2283156 T3 DK2283156 T3 DK 2283156T3
- Authority
- DK
- Denmark
- Prior art keywords
- osteoarthritis
- allele
- vol
- disease
- subject
- Prior art date
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims description 119
- 238000001514 detection method Methods 0.000 title claims description 36
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 title description 3
- 108700028369 Alleles Proteins 0.000 claims description 131
- 238000000034 method Methods 0.000 claims description 83
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 59
- 201000010099 disease Diseases 0.000 claims description 54
- 150000007523 nucleic acids Chemical class 0.000 claims description 45
- 102000039446 nucleic acids Human genes 0.000 claims description 41
- 108020004707 nucleic acids Proteins 0.000 claims description 41
- 108091034117 Oligonucleotide Proteins 0.000 claims description 32
- 230000003321 amplification Effects 0.000 claims description 29
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 29
- 206010061818 Disease progression Diseases 0.000 claims description 25
- 230000005750 disease progression Effects 0.000 claims description 25
- 238000009396 hybridization Methods 0.000 claims description 22
- 238000004458 analytical method Methods 0.000 claims description 13
- 238000003556 assay Methods 0.000 claims description 12
- 238000012163 sequencing technique Methods 0.000 claims description 9
- 238000003776 cleavage reaction Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 230000029087 digestion Effects 0.000 claims description 5
- 102220134620 rs9005 Human genes 0.000 claims description 5
- 230000007717 exclusion Effects 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 110
- 102000000589 Interleukin-1 Human genes 0.000 description 100
- 108090000623 proteins and genes Proteins 0.000 description 68
- 108020004414 DNA Proteins 0.000 description 50
- 102000053602 DNA Human genes 0.000 description 49
- 239000000523 sample Substances 0.000 description 34
- 125000003729 nucleotide group Chemical group 0.000 description 32
- 230000035772 mutation Effects 0.000 description 31
- 102000054766 genetic haplotypes Human genes 0.000 description 29
- 239000002773 nucleotide Substances 0.000 description 29
- 239000013615 primer Substances 0.000 description 29
- 238000003752 polymerase chain reaction Methods 0.000 description 22
- 241000219061 Rheum Species 0.000 description 21
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 102000054765 polymorphisms of proteins Human genes 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- 239000003550 marker Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108091008053 gene clusters Proteins 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 206010003246 arthritis Diseases 0.000 description 12
- 239000013068 control sample Substances 0.000 description 12
- 230000002068 genetic effect Effects 0.000 description 12
- 210000003127 knee Anatomy 0.000 description 12
- 229920002477 rna polymer Polymers 0.000 description 12
- 210000000845 cartilage Anatomy 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000003777 Interleukin-1 beta Human genes 0.000 description 9
- 108090000193 Interleukin-1 beta Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 210000001188 articular cartilage Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000002759 chromosomal effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 6
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 108060002716 Exonuclease Proteins 0.000 description 5
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 5
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 5
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000013165 exonuclease Human genes 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- -1 genomic Chemical class 0.000 description 4
- 210000003917 human chromosome Anatomy 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000007834 ligase chain reaction Methods 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000034311 hand osteoarthritis Diseases 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000010448 genetic screening Methods 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000033607 mismatch repair Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000003234 polygenic effect Effects 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 101150076141 rn gene Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 241001013596 Agestrata Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 108020001738 DNA Glycosylase Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000028381 DNA glycosylase Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000225041 Roestes Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 229960004590 diacerein Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000011979 disease modifying therapy Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000003268 heterogeneous phase assay Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 101150029137 mutY gene Proteins 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 102220134786 rs315952 Human genes 0.000 description 1
- 102220133450 rs419598 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011541 total hip replacement Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4999208P | 2008-05-02 | 2008-05-02 | |
| US11874408P | 2008-12-01 | 2008-12-01 | |
| PCT/US2009/042746 WO2009135218A2 (en) | 2008-05-02 | 2009-05-04 | Detecting genetic predisposition to osteoarthritis associated conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2283156T3 true DK2283156T3 (en) | 2016-02-15 |
Family
ID=41210581
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09740020.4T DK2283156T3 (en) | 2008-05-02 | 2009-05-04 | Detection of genetic predisposition to conditions associated with osteoarthritis |
| DK15193948.5T DK3059323T3 (en) | 2008-05-02 | 2009-05-04 | DETECTION OF GENETIC PREDICTION FOR OSTEOARTHRITIS-ASSOCIATED CONDITIONS |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15193948.5T DK3059323T3 (en) | 2008-05-02 | 2009-05-04 | DETECTION OF GENETIC PREDICTION FOR OSTEOARTHRITIS-ASSOCIATED CONDITIONS |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20100098775A1 (OSRAM) |
| EP (3) | EP2283156B1 (OSRAM) |
| JP (3) | JP5762282B2 (OSRAM) |
| AU (1) | AU2009242490B2 (OSRAM) |
| CA (1) | CA2723239C (OSRAM) |
| DK (2) | DK2283156T3 (OSRAM) |
| ES (2) | ES2708826T3 (OSRAM) |
| NZ (1) | NZ589034A (OSRAM) |
| WO (1) | WO2009135218A2 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2708826T3 (es) * | 2008-05-02 | 2019-04-11 | Orig3N Inc | Detección de la predisposición genética a afecciones asociadas a la osteoartritis |
| US20120115137A1 (en) * | 2010-08-31 | 2012-05-10 | Kornman Kenneth S | Methods of Predicting Osteoarthritis |
| JP6262731B2 (ja) * | 2012-08-06 | 2018-01-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー |
| WO2014023704A1 (en) * | 2012-08-06 | 2014-02-13 | xARES TRADING S.A. | Prognosis biomarkers in cartilage disorders |
| JP2019503176A (ja) | 2016-01-12 | 2019-02-07 | インターロイキン ジェネティクス， インコーポレイテッド | 処置に対する応答を予測するための方法 |
| US10329620B2 (en) | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| LT3688468T (lt) | 2017-09-29 | 2022-06-27 | Merck Patent Gmbh | Uždegiminiai biožymenys, skirti atsako į fgf-18 junginį numatymui |
| CN111163791A (zh) | 2017-09-29 | 2020-05-15 | 默克专利有限公司 | 预测对fgf-18化合物反应性的代谢生物标志物 |
| KR20210057764A (ko) * | 2018-09-10 | 2021-05-21 | 메르크 파텐트 게엠베하 | 골관절염의 치료를 위한 강화 전략에 유용한 마커 |
| EP3886809A4 (en) | 2018-11-28 | 2022-03-30 | Genascence Corporation | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OSTEOARTHRITIS |
| CA3142662A1 (en) | 2019-06-06 | 2020-12-10 | Sitokine Limited | Compositions and methods for treating lung, colorectal and breast cancer |
| WO2021026026A1 (en) * | 2019-08-02 | 2021-02-11 | New York University | Methods and compositions for treating arthritis |
| WO2021028469A1 (en) | 2019-08-12 | 2021-02-18 | Sitokine Limited | Compositions and methods for treating cytokine release syndrome and neurotoxicity |
| WO2021205013A1 (en) | 2020-04-09 | 2021-10-14 | Sitokine Limited | Compositions and methods for treating covid-19 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4998617A (en) | 1986-09-15 | 1991-03-12 | Laura Lupton Inc | Facial cosmetic liquid make up kit |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| EP0679196B1 (en) | 1993-01-07 | 2004-05-26 | Sequenom, Inc. | Dna sequencing by mass spectrometry |
| US5593826A (en) * | 1993-03-22 | 1997-01-14 | Perkin-Elmer Corporation, Applied Biosystems, Inc. | Enzymatic ligation of 3'amino-substituted oligonucleotides |
| US5686246A (en) * | 1995-08-03 | 1997-11-11 | Kornman; Kenneth S. | Detecting genetic predisposition to periodontal disease |
| US5942390A (en) | 1996-01-12 | 1999-08-24 | Cedars-Sinai Medical Center | Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism |
| US5698399A (en) | 1996-04-05 | 1997-12-16 | Duff; Gordon W. | Detecting genetic predisposition for osteoporosis |
| GB9621129D0 (en) * | 1996-10-10 | 1996-11-27 | Duff Gordon W | Detecting genetic predisposition to sight-threatening diabetic retinopathy |
| GB9706359D0 (en) * | 1997-03-27 | 1997-05-14 | Gemini International Holdings | Polymorphisms of an il-1 receptor antagonist gene |
| GB9711040D0 (en) * | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
| KR100924468B1 (ko) * | 2002-01-25 | 2009-11-03 | 인터레우킨 제네틱스, 인코포레이티드 | Ｉｌ-1 유전자 집단 및 관련된 염증성 다형성과 일배체형 |
| CA3050151C (en) * | 2003-11-26 | 2023-03-07 | Celera Corporation | Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof |
| CA2631675A1 (en) * | 2005-11-30 | 2007-06-21 | The University Of North Carolina At Chapel Hill | Identification of genetic polymorphic variants associated with somatosensory disorders and methods of using the same |
| ES2708826T3 (es) * | 2008-05-02 | 2019-04-11 | Orig3N Inc | Detección de la predisposición genética a afecciones asociadas a la osteoartritis |
| US9037472B2 (en) | 2012-04-20 | 2015-05-19 | Nuance Communications, Inc. | Method and system for facilitating communications for a user transaction |
-
2009
- 2009-05-04 ES ES15193948T patent/ES2708826T3/es active Active
- 2009-05-04 ES ES09740020.4T patent/ES2561316T3/es active Active
- 2009-05-04 AU AU2009242490A patent/AU2009242490B2/en not_active Ceased
- 2009-05-04 WO PCT/US2009/042746 patent/WO2009135218A2/en not_active Ceased
- 2009-05-04 CA CA2723239A patent/CA2723239C/en active Active
- 2009-05-04 DK DK09740020.4T patent/DK2283156T3/en active
- 2009-05-04 EP EP09740020.4A patent/EP2283156B1/en not_active Not-in-force
- 2009-05-04 DK DK15193948.5T patent/DK3059323T3/en active
- 2009-05-04 EP EP15193948.5A patent/EP3059323B1/en not_active Not-in-force
- 2009-05-04 EP EP18202413.3A patent/EP3467126A1/en not_active Withdrawn
- 2009-05-04 JP JP2011507714A patent/JP5762282B2/ja active Active
- 2009-05-04 US US12/435,260 patent/US20100098775A1/en not_active Abandoned
- 2009-05-04 NZ NZ589034A patent/NZ589034A/xx not_active IP Right Cessation
-
2015
- 2015-06-09 JP JP2015116397A patent/JP6263499B2/ja active Active
-
2016
- 2016-08-10 US US15/233,122 patent/US20160340734A1/en not_active Abandoned
-
2017
- 2017-12-18 JP JP2017241315A patent/JP2018038436A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015211677A (ja) | 2015-11-26 |
| JP6263499B2 (ja) | 2018-01-17 |
| EP3467126A1 (en) | 2019-04-10 |
| NZ589034A (en) | 2012-10-26 |
| AU2009242490B2 (en) | 2015-01-22 |
| US20160340734A1 (en) | 2016-11-24 |
| JP2011520433A (ja) | 2011-07-21 |
| EP3059323B1 (en) | 2018-12-12 |
| US20100098775A1 (en) | 2010-04-22 |
| WO2009135218A3 (en) | 2010-04-01 |
| CA2723239A1 (en) | 2009-11-05 |
| CA2723239C (en) | 2020-07-21 |
| EP2283156A2 (en) | 2011-02-16 |
| EP2283156B1 (en) | 2015-11-11 |
| WO2009135218A2 (en) | 2009-11-05 |
| JP2018038436A (ja) | 2018-03-15 |
| AU2009242490A1 (en) | 2009-11-05 |
| EP3059323A1 (en) | 2016-08-24 |
| ES2561316T3 (es) | 2016-02-25 |
| DK3059323T3 (en) | 2019-03-04 |
| JP5762282B2 (ja) | 2015-08-12 |
| ES2708826T3 (es) | 2019-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2283156T3 (en) | Detection of genetic predisposition to conditions associated with osteoarthritis | |
| US20100129798A1 (en) | Detecting genetic predisposition to osteoarthritis associated conditions | |
| KR20010024597A (ko) | 만성 폐쇄성 기도 질환에 대한 진단방법 및 치료방법 | |
| AU785040B2 (en) | Diagnostics and therapeutics for osteoporosis | |
| WO2001016377A9 (en) | Diagnostics and therapeutics for osteoporosis | |
| US20100028893A1 (en) | Methods and compositions for pharmacogenetic analysis of anti-inflammatory drugs in the treatment of rheumatoid arthritis and other inflammatory diseases | |
| AU2004263184B2 (en) | Diagnostic and therapeutics for osteoporosis | |
| US20090023147A1 (en) | Diagnostics and therapeutics for osteoporosis | |
| HK40012992A (en) | Detecting genetic predisposition to osteoarthritis associated conditions | |
| HK1225079A1 (en) | Detecting genetic predisposition to osteoarthritis associated conditions | |
| HK1225079B (en) | Detecting genetic predisposition to osteoarthritis associated conditions | |
| AU2015202038A1 (en) | Detecting Genetic Predisposition To Osteoarthritis Associated Conditions | |
| EP1029079A2 (en) | Diagnostics and therapeutics for chronic obstructive airway disease | |
| HK1093757B (en) | Diagnostic for osteoporosis |